Institute of Virology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hermann-Herder-Str. 11, 79014, Freiburg, Germany.
Technical University Munich, School of Medicine, Institute for Medical Microbiology, Immunology and Hygiene, Munich, Germany.
Infection. 2020 Dec;48(6):971-974. doi: 10.1007/s15010-020-01471-y. Epub 2020 Jul 3.
The first SARS-CoV-2 cases in Europe were reported in January 2020. Recently, concern arose on unrecognized infections before this date. For a better understanding of the pandemic, we retrospectively analyzed patient samples for SARS-CoV-2 from the prospective CAPNETZ study cohort.
We used nasopharyngeal swab samples from a cohort of well characterized patients with community acquired pneumonia of the CAPNETZ study group, recruited from different geographic regions across Germany, Austria, the Netherlands, and Switzerland between 02nd December 2019 and 28th April 2020. Multiplex real-time RT-PCR for a broad range of respiratory pathogens and SARS-CoV-2 real-time RT-PCR were performed on all samples.
In our cohort, respiratory pathogens other than SARS-CoV-2 were detected in 21.5% (42/195) of patients with rhinovirus as the most frequently detected pathogen. The detection rate increased to 29.7% (58/195) when SARS-CoV-2 was included. No SARS-CoV-2 positive sample was detected before end of March 2020.
Respiratory viral pathogens accounted for a considerable number of positive results but no SARS-CoV-2 case was identified before the end of March 2020.
欧洲首例 SARS-CoV-2 病例于 2020 年 1 月报告。最近,人们对该日期之前未被识别的感染表示担忧。为了更好地了解大流行情况,我们回顾性分析了来自前瞻性 CAPNETZ 研究队列的 SARS-CoV-2 患者样本。
我们使用了来自 CAPNETZ 研究组的具有明确特征的社区获得性肺炎患者队列的鼻咽拭子样本,这些患者于 2019 年 12 月 2 日至 2020 年 4 月 28 日期间从德国、奥地利、荷兰和瑞士的不同地理区域招募。对所有样本进行了多种呼吸道病原体和 SARS-CoV-2 的实时 RT-PCR 检测。
在我们的队列中,除 SARS-CoV-2 以外的呼吸道病原体在 21.5%(42/195)的患者中被检测到,其中鼻病毒是最常检测到的病原体。当包括 SARS-CoV-2 时,检测率增加到 29.7%(58/195)。在 2020 年 3 月底之前,未检测到 SARS-CoV-2 阳性样本。
呼吸道病毒病原体占阳性结果的相当一部分,但在 2020 年 3 月底之前未发现 SARS-CoV-2 病例。